KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases

On September 17, 2019 KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, reported that its president and chief executive officer, Travis C. Mickle, Ph.D., will host one-on-one meetings with investors at the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases being held September 23-24, 2019, at the Parker New York Hotel (Press release, KemPharm, SEP 17, 2019, View Source [SID1234539584]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the conference are as follows:

Event: Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases
Dates: September 23-24, 2019
Format: One-on-One Meetings
Location: Parker New York Hotel, New York, NY
The Oppenheimer Fall Summit brings together the management teams from a select group of companies focused on specialty pharmaceuticals and orphan and rare diseases with investors to discuss therapeutic programs in development and recent corporate updates. During the one-on-one meetings, Dr. Mickle will discuss KemPharm’s recent strategic commercial partnering transaction, its corporate growth strategy and its focus on utilizing its proprietary LATTM (Ligand Activated Therapy) platform technology to discover and develop improved prodrug versions of FDA-approved drugs as well as prodrug versions of existing compounds that may have applications for new disease indications.

KemPharm’s prodrug product candidate pipeline is highlighted by its co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, which are based on a prodrug of d-methylphenidate. On September 4th, 2019, KemPharm announced a $493 million definitive collaboration and license agreement with an affiliate of Gurnet Point Capital (GPC) that provides the affiliate with exclusive worldwide rights to develop, manufacture and commercialize KP415 and KP484.